COMPUMEDICS ORD
Compumedics Looks to Turn the Corner after Record Sales And Growth in FY25
Compumedics (ASX: CMP) has marked a strategic turning point in its development after posting record sales and profitable growth for the 2025 financial year. The company racked up $63.4 million in sales for the period, representing a growth of 22% on the previous year. Its EBITDA increased to approximately $3m, returning Compumedics to profitability and […]
Compumedics reaches $20m in Chinese MEG sales with latest university contract
Brain research technologies specialist Compumedics (ASX: CMP) has reached $20 million in sales for its magnetoencephalography (MEG) system in China. The latest $5.7m contract from Hangzhou Normal University follows the successful installation of a MEG system at Tianjin Normal University and further orders from Tsinghua and Tianjin universities. MEG is a neuroimaging technique for mapping […]
Compumedics eyes US market with Somfit sleep diagnostic device
Brain research technology specialist Compumedics (ASX: CMP) has achieved a major breakthrough with the planned distribution of its Somfit sleep assist system, with the Food & Drug Administration (FDA) clearing the device to be marketed in the United States. Compumedics is targeting the multi-million dollar sleep market in the US with the Somfit technology, which […]
US FDA approves Compumedics’ MEG neuroimaging technology enabling insurers to be billed
Compumedics (ASX: CMP) has collared US Food and Drug Administration approval for its neuroimaging technology, enabling insurers to be billed for the scan. On Friday, the FDA officially granted 510(K) clearance to Compumedics for its Orion LifeSpan Magnetoencephalography (MEG) single Dewar system. Compumedics’ MEG is a neuroimaging technique that maps brain activity by recording magnetic […]
